Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib as Maintenance Therapy Following Allo-HCT in AML
NCT06440135Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziftomenib in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2024; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06440135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440135.